Prostacyclin (PG12), originally described by Moncada et al. (1) , has been shown to be a potent inhibitor of platelet aggregation. PGI2 is a naturally occurring compound in many tissues including the vascular endothelium (2) . It is a potent vasodilator (3) and inhibitor of platelet aggregation (4). It enhances platelet cAMP level (5, 6). Some investigators think that it regresses the imbalance which may result from the excess thromboxane for mation in the disease state (7). Thus PGI2 may play important role in the prevention of thrombus formation. Prostacyclin has been used in hemoperfusion (8), in cardio-bypass surgery (9) and in certain peripheral vascular disorders (10, 11), although its instability (12, 13) and hypotensive activity by a polyethylene catheter (PE100, Clay Adams), which was filled with heparin solution (100 U/ml, Novo). It was lead subcutaneously to a small incision in the back side of the neck. The end was connected to a three way stopcock and fixed. On the next day, blood pressure was monitored through one end of the stopcock, and the blood sampling was made from another outlet. Five ml blood was collected into the syringe filled with 1/10 volume of 3.8% sodium citrate solution, 65 min and 5 min before drug ad ministration and 30, 60, 120, 180, 240 and 300 min after drug administration. The blood was processed and PRP was prepared as described in the in vitro test. The platelet count in the PRP was adjusted to 35 x 104/mm3 with PPP using a Coulter counter (Coulter Electronic, Ltd., U.K.). The aggregation rate was calcula ted against the turbidity of PPP, which was designated as 100%.
2.2. Rat: Male Wistar rats (Shizuoka Laboratory Animal Center), 8 to 9 weeks old, fasted 20 hr, were used. TRK-100 was ad ministered orally at the dose of 0.1, 0.3, 1 or 3 mg/kg to the test groups (4 rats for each time point) and 1 ml/kg of distilled water was given to the control rats (12 rats). Under ether anesthesia, 10 ml blood was collected from the carotid artery into a centrifugation tube containing 1/10 volume of 3.8% sodium citrate at the time of 0.5, 1, 3 and 5 hr after administration of the drug. The rats were sacrificed by inhalation of chloroform. The blood was processed, and its platelet ag gregation was tested as described in the in vitro test. Blood pressure was measured in other Wistar rats (weighing 300-400 g) after chronic catheter (PE50) implantation in the carotid artery. Blood pressure and heart rate was recorded on a polygraph (Nihon Kohden AT600G). The effect of TRK-100 was deter mined by oral administration.
Platelet disaggregation
The disaggragating effect of the drugs was measured against ADP (2.5-15 ttM) induced aggregation in human platelets. Each drug was added to the PRP after aggregation induced by ADP reached the maximal response. The optimal concentration of ADP to induce submaximal aggregation was deter mined by increasing the concentration of ADP, beforehand, for each of the volunteers. The extent of disaggregation was estimated by recovery of the transparency of the PRP after addition of drugs. The concentration required to disaggregate 50% of the maximal aggrega tion was expressed as the IC50 and calculated from the dose-response curve. The potency was compared with PG 12 and the potency ratio to PG12 (PG12 ratio) was calculated as suming the potency of PG12 to be 1.0.
Cyclic AMP determination
The cAMP level of platelets was determined by radioimmunoassay with an RIA kit (Boehringer).
Blood was collected from two volunteers in each experiment, and PRP was prepared by the method as described for the in vitro aggregation study. The PRP was pooled for the following experiments.
The PRP sample was incubated at 37°C with vari ous doses of TRK-100 and PG12 for 1 min in the dose-response study and for different in tervals (0 to 300 sec) in the time course study. The incubation was terminated by addition of 5% trichloroacetic acid and then frozen in liquid nitrogen. The platelets were disrupted by an ultrasonic cell disrupter. After centrifu gation at 13,000 rpm for 30 min, the super natant was collected and extracted by ether. The sample was assayed in duplicate for cAM P using the RIA kit. The amount of cAMP was calculated and expressed as cAM P level (pmol) per 109 cells. In the same platelets, inhibition by drugs of aggregation induced by ADP (5 ,iM) was determined.
Effect of theophylline (0.1 mM) pretreatment on the platelet cAM P level, and inhibition of ag gregation by TRK-100 was also determined. Theophylline was added 1 min before addition of TRK-100 or PG 12.
Statistical analysis
Results were expressed as the mean+ standard error. Statistical significance was calculated by Student's t-test or the paired t-test and IC50 by the probit method.
Results

Platelet aggregation inhibition 1.I n vitro
In the human platelets, TRK-100 inhibited platelet aggregation induced by ADP and collagen. The IC50 values are shown in Table  1 a. The potency ratio was in the range of 0.21 to 0.53 of PG12. A.A. induced aggregation was not seen in the human platelets up to 100 ,ag/ml. A higher concentration could not be tested, because of the interference by the vehicle for the A.A. solution (ethanol). In the rabbit platelets, the PG 12 ratio was about 0.1, showing that TRK-100 had a weak potency in this species (Table 1 b ). In the guinea-pig platelets; PG12 ratio was approximately 0.2. The sensitivities to the aggregation inducers were relatively high, but the IC50 values in rabbits were not as low as those in human platelets (Table 1 c) . In rat platelets, for ADP induced aggregation, the PG 12 ratio was about 0.2. The rat platelets did not aggregate in response to collagen and A.A., at concen trations up to 10 ag/ml and 100 fig/ml, respectively, although higher concentrations were not tested (Table 1d ). In the dog, ADP and A.A. induced platelet aggregation was inhibited dose-dependently, and the IC50 values are shown in Table l e. Inhibition of collagen induced aggregation was not tested in this species. In the cat, platelet aggregation was induced by ADP, collagen and A.A. at relatively low threshold concentrations. In this species, the TRK-100 showed com parable potency to PG12, although the IC50 value of PG12 was rather high (Table 1f) The duration of action was 1 hr at 0.3 mg/kg and over 5 hr at 1 mg/ kg (Table 2a) . At these doses, no significant effects on blood pressure were observed (Table 2b ).
1.2.2. Anesthetized rabbits: TRK-100 at the doses of 0.03 mg/kg to 0.3 mg/kg inhi bited ADP and A.A.-induced platelet ag gregation. Its duration of action was longer than that in the conscious animal (Table 3a) , but blood pressure depression was obvious (Table 3b ). Enhancement of aggregation was observed in the later phase of lower doses.
1.2.3. Conscious rats: I n the rat, TRK-100 in the dose range of 0.1 to 1 mg/kg inhibited platelet aggregation dose-dependently. The inhibition was significant until 6 hr after administration.
No significant change was observed for platelet count (data not shown). The effect on blood pressure was observed at high dose, and transient elevation of heart rate was observed 30 min after drug adminis tration (Fig. 2) .
Disaggregation
The aggregation of ADP was reversed by TRK-100, PG12 and IC50 and PG12 ratio are shown in Table 4 . The concentration of ADP to induce aggregation ranged from 2.5 to 15 ,uM depending on the individual. The IC50 of each of the volunteers varied individually de pending on the concentration of ADP used to induce aggregation.
The approximate potency of TRK-100 was about half that of PG12, which is comparable to the PG12 ratio in the aggregation inhibition study. Fig. 3 . Accumulation of cAMP began quickly after incubation with TRK-100 and PG 12 at the dose of 100 ng/ml and reached a plateau level at 10 min. 3.2. Dose-response curve Dose-response curves of TRK-100 on platelet cAMP are shown in Fig. 4 . Dose response of TRK-100 to the inhibition of aggregation in the same platelets was super imposed on the same figure. The potency of TRK-100 was about 0.5 that of PG 12 in cAM P level and 0.2 in the inhibition of platelet aggregation.
The effect of TRK-100 was enhanced by addition of theophylline (0.1 mM) as shown in Fig. 5 . The enhancement was about 30% at the concentration of 100 ng/ml of TRK-100. Theophylline alone inhi bited platelet aggregation about 45%. The vertical bar represents the standard error of the mean. *P<0.05, **P<0.01 : statis tically significant difference from the predrug control value. 
Discussion
A strong inhibition of the platelet aggrega tion by TRK-100 was shown in al I the species tested, but the potency differed from species to species. This difference was observed also with PGI2, in accordance with the other report (4). However, species difference of PGI2 was somewhat smaller than that for TRK-100. The potency of the analog was strong in human and cat platelets. Thus, the PGI2 ratio was large in human and cat platelets and smallest in rabbit platelets. This may suggest that TRK-100 has a different affinity to the PGI2 receptors in the species tested. The mechanism for the inhibition of platelet aggregation inhibition by PGI2 is thought to be enhancement of the cAM P level in the platelets (5, 6). The same mechanism may play a role in the inhibition of aggregation by TRK-100, since it also enhanced the cAM P level of platelets. The enhancement was aug (100 ng/ml, -0-) and TRK-100 (100 ng/ml, -0-).
Each point the repre sents the mean of duplicate measure ments. mented by theophylline with concomitant augmentation in the aggregation inhibition by TRK-100. Ex vivo platelet aggregation was also shown in both rabbits and rats by the oral route with minimal effect on blood pressure in conscious rabbits, but not in anesthetized rabbits. Vagal reflex was reported to be in volved in the vasodilatation and blood pres sure depression of PG12 in anesthetized dogs (21). The hypotension in anesthetized rabbits might have caused by the enhancement of reflex vasodilatation by the anesthetizing agent.
Enhancement of ex vivo platelet aggregation was observed in anesthetized rabbits at 0.03 mg/kg and 0.1 mg/kg groups, although the extent differed depending on the aggregation inducers. This may have resulted from the blood loss by frequent blood sampling and addition of anesthetizing agent. In higher doses, the enhancement may have been masked by the platelet inhibition effect of TRK-100. PG12 has been used clinically with success as a heparin substitute in extracorporal circu lation (8) and peripheral arterial disease. However, the chemical (12) and biological (13) instability restricted extended clinical applications.
TRK-100 is chemically stable and has a rather long-lasting pharmacological effect ex vivo when given by the oral route. The blood pressure depression is another adverse effect of PG12, which also restricted the clinical applicability of PG12. However, in conscious animals at a sufficient dose to show the antiplatelet effect, the effect of oral TRK-100 on blood pressure was minimal, as shown in the rabbit ex vivo study. potential antithrombotic which can be ad ministered orally.
